Study hammers last nail in the coffin for Bayer's Trasylol

Share this article:

New study findings caused Bayer to begin withdrawing supplies of its antifibrinolytic drug, Trasylol (aprotinin injection), from the US market. Trasylol marketing efforts were suspended by the FDA, in November 2007, after preliminary study results suggested increases in the risk of death in patients, compared with two other drugs used to control bleeding, the FDA said in a statement.
The study, Blood conservation using antifibrinolytics: A randomized trial in a cardiac surgery population (dubbed BART), was published in the New England Journal of Medicine (NEJM). According to NEJM, the study found aprotinin to be the most effective hemostatic agent in comparison with lysine analogues. However, “at 30 days, patients who were receiving aprotinin in BART had an increased risk of death of more than 50% ... an outcome that led trial investigators to conclude that aprotinin should no longer be used in patients undergoing high-risk cardiac surgery.”

Given Trasylol's "temporary market suspension worldwide" beginning November 5th, 2007, Bayer doesn't expect any commercial impact as a result of the NEJM article, according to Staci Gouveia, manager of global communications at Bayer. "On December 17, Bayer HealthCare Pharmaceuticals announced that the company would realign portions of its US marketing and sales force.  Driving this realignment was a decision that, independent of forthcoming BART Trial data results, the company would not return to actively promoting Trayslol in the United States and discontinue the promotion of Refludan."

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...